Intocell Recruits BD Experts to Expand Global Business Operations

by Jang Hyowon

Published 21 Oct.2025 09:21(KST)

From the left, Koo Eunyeong, Executive Director of Business Development Center at Intocell, Jang Jinhyuk, Team Leader. Provided by Intocell

Intocell has recently completed a reorganization of its business development (BD) division, strengthening its internal structure. Having raised its profile through platform commercialization agreements involving linkers and payloads, the company is now expected to accelerate the expansion of its global partnerships with the recruitment of new talent.

According to industry sources on October 21, Intocell recently recruited Koo Eunyeong, who previously led business development at Toolgen, as Executive Director. In addition, the company brought on board Jang Jinhyuk, former Business Development Manager at InnoCure Therapeutics, along with other professionals with extensive hands-on BD experience.

The newly appointed Head of Business Development Center, Koo Eunyeong (Executive Director), holds a Ph.D. in Science from the University of Illinois and has worked as a researcher at Northwestern University and the University of Chicago. She later served as Head of Business Development at AtoGen, a subsidiary of cosmetics manufacturer and distributor Tony Moly, which is a microbiome-based new drug development biotech venture. At Toolgen, she oversaw technology transfer for major pipelines and patents as Head of Business Development.

Team Leader Jang Jinhyuk majored in Life Sciences at the University of Toronto in Canada and graduated from the Graduate School of Pharmaceutical Industry at Sungkyunkwan University. He has experience in regulatory affairs, business development, and fundraising at both domestic and international companies. His strengths lie in his diverse business development experience at companies such as Merck, the German multinational pharmaceutical company, as well as Whanin Pharmaceutical, Corestem ChemOn, and InnoCure Therapeutics.

With these new BD hires, Intocell has effectively completed the reorganization of its BD capabilities. According to industry sources, Intocell has been accelerating the reinforcement of its BD team in preparation for its upcoming IPO and global business expansion. In particular, the company has filled the organizational gap that arose after the departure of former Executive Director Moon Sungjoo, thereby establishing a stable internal foundation.

The BD division is considered a core department that directly impacts corporate value through technology transfer of new drugs and the expansion of global alliances. Beyond simple sales functions, it plays a strategic role in designing partnerships that encompass both technology and the market, making BD professionals key assets driving the growth of biotech companies.

Meanwhile, Intocell is strengthening its global competitiveness with next-generation linker and payload-based antibody-drug conjugate (ADC) platform technology. Intocell's platform, centered on the OHPAS linker and PMT technology, is recognized for overcoming the limitations of conventional linker technologies by simultaneously achieving drug safety and toxicity control.

Recently, as the company has expanded contracts with major partners and made visible progress in clinical development of its pipeline, expectations for technology validation have been rising.

This latest recruitment of BD professionals aligns with Intocell's strategy to accelerate its growth.

Intocell plans to go beyond technology-driven growth by strengthening its global business development capabilities, with the aim of significantly expanding technology transfer and establishing new partnerships for its pipeline. Through this, the company intends to accelerate the commercialization of its platform technology and drive growth centered on technology business development.

An Intocell representative stated, "We expect to secure clinical data in the near future, and as collaborations with global big pharma are anticipated to expand, the recent strengthening of our BD organization will further enhance Intocell's growth potential and ability to commercialize its technology. Based on our differentiated linker and payload technologies, we aim to become a globally competitive biotech company."